Winning the asymmetric war: New strategies for combating antibacterial resistance

Future Microbiology

Volumn 3, Issue 2, 2008, Pages 119-123

  Potts, Rebekah G ^a   Lujan, Scott A ^a   Redinbo, Matthew R ^a  

^a University of North Carolina at Chapel Hill   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; ANTIRETROVIRUS AGENT; BETA LACTAM ANTIBIOTIC; BISPHOSPHONIC ACID DERIVATIVE; DEOXYRIBONUCLEASE; DNA; ETHAMBUTOL; GYRASE INHIBITOR; INSULIN; ISONIAZID; METFORMIN; METICILLIN; PYRAZINAMIDE; REACTIVE OXYGEN METABOLITE; RECA PROTEIN; REPAGLINIDE; RIBONUCLEASE; RIFAMPICIN; RNA DIRECTED DNA POLYMERASE INHIBITOR; STREPTOMYCIN; SULFONYLUREA; THIOACETAZONE; TROGLITAZONE; VANCOMYCIN;

ACINETOBACTER BAUMANNII; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIMICROBIAL THERAPY; BACTERIAL INFECTION; DIABETES MELLITUS; DNA TRANSFER; DRUG POTENTIATION; DRUG TARGETING; EDITORIAL; ESCHERICHIA COLI; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MORTALITY; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; PROTEIN SYNTHESIS INHIBITION; STAPHYLOCOCCUS INFECTION; TUBERCULOSIS; WOUND INFECTION;

ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; DRUG RESISTANCE, BACTERIAL; HUMANS;

EID: 47249108516     PISSN: 17460913     EISSN: None     Source Type: Journal    
DOI: 10.2217/17460913.3.2.119     Document Type: Editorial

References (53)

1. Klevens R, Edwards JR, Richards CL Jr et al.: Estimating health care-associated infections and deaths in U.S. hospitals, 2002. Public Health Rep. 122, 160-166 (2007).
2. Cancer Facts and Figures, 2007. American Cancer Society, Atlanta, GA, USA, p. 4 (2007).
3. Hardy B: The issue of antibiotic use in the livestock industry: what have we learned? Anim. Biotechnol. 13, 129-147 (2002).
4. WHO global strategy for containment of antimicrobial resistance. World Health Organization. Department of Communicable Disease Surveillance and Response. Geneva, Switzerland, p. 11-39 (2001).
5. Furuya E, Lowy FD: Antimicrobial-resistant bacteria in the community setting. Nat. Rev. Microbiol. 4, 36-45 (2006).
6. Amabile-Cuevase C: New antibiotics and new resistance. Am. Sci. 91, 138-139 (2003).
7. Clatworthy A, Pierson E, Hung DT: Targeting virulence: a new paradigm for antimicrobial therapy. Nat. Chem. Biol. 3, 541-548 (2007).
8. Walsh C: Where will new antibiotics come from? Nat. Rev. Micrbiol. 1, 65-70 (2003).
9. Lujan S, Guogas LM, Ragonese H, Matson SW, Redinbo MR: Disrupting antibiotic resistance propagation by inhibiting the conjugative DNA relaxase. Proc. Natl Acad. Sci. USA 104, 12282-12287 (2007).
10. Fernandez-Lopez R, Machon C, Longshaw CM et al.: Unsaturated fatty acids are inhibitors of bacterial conjugation. Microbiology 151, 3517-3626 (2005).
11. Garcillan-Barcia M, Jurado P. Gonzalez-Perez B, Moncallan G, Fernandez LA, de la Cruz F: Conjugative transfer can be inhibited by blocking relaxase activity within recipient cells with intrabodies. Mol. Microbiol. 63, 404-416 (2007).
12. Shankar R, He L, Szilagyi A et al.: A novel antibacterial gene transfer treatment for multidrug-resistant Acinetobacter Baumannii-induced burn sepsis. J. Burn Care Res. 28, 6-12 (2007).
13. Lederberg J, Tatum EL: Gene recombination in Esherichia coli. Nature 158, 558 (1946).
14. de la Cruz F, Davies J: Horizontal gene transfer and the origin of species: lessons from bacteria. Trends Microbiol. 8, 128-133 (2000).
15. Alekshun M, Levy SB: Molecular mechanisms of antibacterial multidrug resistance. Cell 128, 1037-1050 (2007).
16. Lanka E, Wilkins BM: DNA processing reactions in bacterial conjugation. Annu. Rev. Biochem. 64, 141-169 (1995).
17. Mazel D, Davies J: Antibiotic resistance in microbes. Cell. Mol. Life Sci. 56, 742-754 (1999).
18. Centers for Disease Control and Prevention. Stapbylococcus aureas resistant to vancomycin - United States, 2002. MMWR Morb. Mortal Wkly Rep. 51(26), 565-567 (2002).
19. Larkin C, Datta S, Harley MJ et al.: Inter- and intramolecular determinants of the specificity of single-stranded DNA binding and cleavage by the F factor relaxase. Structure 13, 1533-1544 (2005).
20. Datta S, Larkin C, Schildbach JF: Structural insights into single-stranded DNA binding and cleavage by F factor TraI. Structure 11, 1369-1379 (2003).
21. Boer R, Russi S, Guasch A et al.: Unveiling the molecular mechanism of a conjugative relaxase: the structure of TrwC complexed with a 27-mer DNA comprising the recognition hairpin and the cleavage site. J. Mol. Biol. 358, 857-869 (2006).
22. Smith P, Romesberg FE: Combating bacteria and drug resistance by inhibiting mechanisms of persistence and adaptation. Nat. Chem. Biol. 3, 549-556 (2007).
23. Dwyer D, Kohanski MA, Hayete B, Collins JJ: Gyrase inhibitors induce an oxidative damage cellular death pathway in Escherichia coli. Mol. Syst. Biol. 3, 91 (2007).
24. Kohanski M, Dwyer DJ, Hayete B, Lawrence CA, Collins JJ: A common mechanism of cellular death induced by bactericidal antibiotics. Cell 130, 797-810 (2007).
25. Miller C, Thomsen LE, Gaggero C, Mosseri R, Ingmer H, Cohen SN: SOS response induction by β-lactams and bacterial defense against antibiotic lethality. Science 305, 1629-1631 (2004).
26. Zimmermann G, Lehar J, Keith CT: Multi-target therapeutics: when the whole is greater than the sum of the parts. Drug Discov. Today 12, 34-42 (2007).
27. Tanoue L, Gettinger S: Treatment of lung cancer in older patients. Clin. Chest Med. 29, 735-749 (2007).
28. Sorenson S, Glimelius B, Nygren P: A systematic overview of chemotherapy effects in non-small cell lung cancer. Acta Oncol. 40, 327-339 (2001).
29. Garber A: Strategies for better diabetes control in the US. Drugs 58, 61-69 (1999).
30. Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach. World Health Organization. Geneva, Switzerland, p. 17-23, 40-42 (2006).
31. What is DOTS? A guide to understanding the WHO - recommended TB control strategy known as DOTS. World Health Organization. Communicable Disease Cluster, Prevention and Control. Geneva, Switzerland, p. 14-18 (1999).
32. Brown N, Korner RJ, Zollman CE, Martin RP, Millar MR: Ciprofloxacin treatment of bacterial endocarditis involving prosthetic material after cardiac surgery. Arch. Dis. Child. 76, 68-69 (1997).
33. Chernish R, Aaron SD: Approach to resistant Gram-negative bacterial pulmonary infections in patients with cystic fibrosis. Curr. Opin. Pulm. Med. 9, 509-515 (2003).
34. Vergara M, Vallve M, Gisbert JP, Calvet X: Meta-analysis: comparative efficacy of different proton-pump inhibitors in triple therapy for Helicobacter pylori eradication. Aliment. Pharmcol. Ther. 18, 647-654 (2003).
35. Patel S, Saravolatz LD: Monotherapy versus combination therapy. Med. Clin. North Am. 90, 1183-1195 (2006).
36. Zhu W, Clark NC, McDougal LK, Hageman J, McDonald LC, Patel JB: Vancomycin-resistant Staphylococcus aureus isolates associated with Inc18-like vanA plasmids in Michigan. Antimicrob. Agents Chemother. 52, 452-457 (2008).
37. Palazzo I, Araujo ML, Darini AL: First report of vancomycin-resistant staphylococci isolated from healthy carriers in Brazil. J. Clin. Microbiol. 43, 179-85 (2005).
38. Tiwari H, Sen MR: Emergence of vancomycin resistant Staphylococcus aureus (VRSA) from a tertiary care hospital from northern part of India. BMC Infect. Dis. 6, 156 (2006).
39. Saha B, Singh AK Ghosh A, Bal M: Identification and characterization of a vancomycin-resistant Staphylococcus aureus isolated from Kolkata (South Asia). J. Med. Microbiol. 57, 72-79 (2008).
40. Tenover F, Weigel LM, Appelbaum PC et al.: Vancomycin-resistant Staphylococcus aureus isolate from a patient in Pennsylvania. Antimicrob. Agents Chemother. 48, 275-280 (2004).
41. Flannagan S, Chow JW, Donabedian SM et al.: Plasmid content of a vancomycin-resistant Enterococcus faecalis isolate from a patient also colonized by Staphylococcus aureus with a VanA phenotype. Antimicrob. Agents Chemother. 47, 3954-3959 (2003).
42. Hanaki H, Kuwahara-Arai K, Boyle-Vavra S. Daum RS, Labischinski H, Hiramatsu K: Activated cell-wall synthesis is associated with vancomycin resistance in methicillin-resistant Staphylococcus aureus clinical strains Mu3 and Mu50. J Antimicrob. Chemother. 42, 199-209 (1998).
43. Hanaki H, Labischinski H, Inaba Y, Kondo N, Murakami H, Hiramatsu K: Increase in glutamine-non-amidated muropeptides in the peptidoglycan of vancomycin-resistant Staphylococcus aureus strain Mu50. J Antimicrob. Chemother. 42, 315-320 (1998).
44. Cui L, Murakami H, Kuwahara-Arai K, Hanaki H, Hiramatsu K: Contribution of a thickened cell wall and its glutamine nonamidated component to the vancomycin resistance expressed by Staphylococcus aureus Mu50. J. Antimicrob. Chemother: 44, 2276-2285 (2000).
45. Weigel L, Donlan RM, Shin DH et al.: High-level vancomycin-resistant Staphylococcus aureus isolates associated with a polymicrobial biofilm. Antimicrob. Agents Chemother. 51, 231-238 (2007).
46. Showsh S, De Boever EH, Clewell DB: Vancomycin resistance plasmid in Enterococcus faecalis that encodes sensitivity to a sex pheromone also produced by Staphylococcus aureus. Antimicrob. Agents Chemother. 45, 2177-2178 (2001).
47. Perichon B, Courvalin P: Synergism between β-lactams and glycopeptides against VanA-type methicillin-resistant Staphylococcus aureus and heterologous expression of the vanA operon. Antimicrob. Agents Chemother. 50, 3622-3630 (2006).
48. Severin A, Tabei K, Tenover F, Chung M, Clarke N, Tomasz A: High level oxacillin and vancomycin resistance and altered cell wall composition in Staphylococcus aureus carrying the staphylococcal mecA and the enterococcal vanA gene complex. J. Biol. Chem. 279, 3398-3407 (2004).
49. Severin A, Wu SW, Tabei K, Tomasz A: Penicillin-binding protein 2 is essential for expression of high-level vancomycin resistance and cell wall synthesis in vancomycin-resistant Staphylococcus aureus carrying the enterococcal vanA gene complex. Antimicrob. Agents Chemother. 48, 4566-4573 (2004).
50. Chandler J, Flynn AR, Bryan EM, Dunny GM: Specific control of endogenous cCF10 pheromone by a conserved domain of the pCF10-encoded regulatory protein PrgY in Interococcus faecalis. J. Bacteriol. 187, 4830-4843 (2005).
51. Qiu X, Wang H, Lu XF et al.: An engineered multidomain bactericidal peptide as a model for targeted antibiotics against specific bacteria. Nat. Biotechnol. 21, 1480-1485 (2003).
52. Qiu X, Zhang J, Wang H, Wu GY: A novel engineered peptide, a narrow-spectrum antibiotic, is effective against vancomycin-resistant Enterococcus faecalis. Antimicrob. Agents Chemother. 49, 1184-1189 (2005).
53. Hancock R, Sahl HG: Antimicrobial and host-defense peptides as new anti-infective therapeutic strategies. Nat. Biotechnol. 24, 1551-1557 (2006).